- Open
- 33.00
- High
- 34.00
- Low
- 31.00
- Close
- 34.00
- Change
- -1.00 (-3.03%)
- Volume
- 35,633
| 27 Jul 2026 | 07:52:18 | Trading Update |
| 23 Jul 2026 | 11:04:40 | TR-1: Notification of Major Holdings |
| 22 Jul 2026 | 16:01:02 | TR-1: Notification of Major Holdings |
| 15 Jul 2026 | 14:06:48 | TR-1: Notification of Major Holdings |
| 10 Jul 2026 | 12:15:01 | Result of GM, TVR & Director/PDMR Dealing |
| 25 Jun 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 1 Jul 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 4 Jul 2024 | Annual Report and Accounts (to 2023-12-31) |
Cambridge Cognition Holdings PLC develops proprietary technologies for cognitive assessment, focusing on brain health. Its primary products include digital touchscreen assessments known as CANTAB® and voice-based assessments, enhanced through the acquisition of Winterlight Labs. The company serves four market segments: Clinical Studies, Academic Research, Healthcare, and Consumer Health & Wellness, with a significant portion of revenue derived from supporting clinical studies for pharmaceutical companies. Cambridge Cognition operates primarily in the healthcare sector, targeting customers in clinical, academic, and consumer markets globally.
| 27 Jul 2026 | 07:52:18 | Trading Update |
| 23 Jul 2026 | 11:04:40 | TR-1: Notification of Major Holdings |
| 22 Jul 2026 | 16:01:02 | TR-1: Notification of Major Holdings |
| 15 Jul 2026 | 14:06:48 | TR-1: Notification of Major Holdings |
| 10 Jul 2026 | 12:15:01 | Result of GM, TVR & Director/PDMR Dealing |
| 25 Jun 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 1 Jul 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 4 Jul 2024 | Annual Report and Accounts (to 2023-12-31) |
Cambridge Cognition Holdings PLC develops proprietary technologies for cognitive assessment, focusing on brain health. Its primary products include digital touchscreen assessments known as CANTAB® and voice-based assessments, enhanced through the acquisition of Winterlight Labs. The company serves four market segments: Clinical Studies, Academic Research, Healthcare, and Consumer Health & Wellness, with a significant portion of revenue derived from supporting clinical studies for pharmaceutical companies. Cambridge Cognition operates primarily in the healthcare sector, targeting customers in clinical, academic, and consumer markets globally.
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £30.92bn | -0.0% | |
| £30m | — | |
| £17m | -0.4% | |
COGCambridge Cognition Holdings PLC | £14m | +0.3% |
| £5m | -0.5% | |
| £3m | -1.0% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £30.92bn | -0.0% | |
| £30m | — | |
| £17m | -0.4% | |
COGCambridge Cognition Holdings PLC | £14m | +0.3% |
| £5m | -0.5% | |
| £3m | -1.0% |